6.20Open6.20Pre Close0 Volume263 Open Interest220.00Strike Price0.00Turnover88.21%IV15.50%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry6.20Extrinsic Value100Contract SizeAmericanOptions Type-0.2041Delta0.0058Gamma40.81Leverage Ratio-0.3899Theta-0.0261Rho-8.33Eff Leverage0.1579Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet